US5945290A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Antisense modulation of RhoA expression
Assignee: Ionis Pharmaceuticals Inc
•
Filing: 1998-09-18
•
Granted: 1999-08-31
•
Expires: 2018-09-18
Abstract
Abstract Antisense compounds, compositions and methods are provided for modulating the expression of RhoA. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RhoA. Methods of using these compounds for modulation of RhoA expression and for treatment of diseases associated with expression of RhoA are provided.
Inventors
- 👤 Lex M. Cowsert
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 12:33
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; C12N15/1137; C12Q; C12Q1/00; C12Q1/68; C12Q1/6813; C12Q1/6816; C12Q1/6818; C12Y; C12Y301/00; C12Y301/05; C12Y301/05001; C12N2310/00; C12N2310/30; C12N2310/31; C12N2310/315; C12N2310/316; C12N2310/318; C12N2310/3183; C12N2310/32; C12N2310/321; C12N2310/322; C12N2310/33; C12N2310/334; C12N2310/335; C12N2310/34; C12N2310/341; C12N2310/345; C12N2310/346
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
28 words
An antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding human RhoA, wherein said antisense compound inhibits the expression of human RhoA.
Claim 2
Dependent Claim
28 words
An antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding human RhoA, wherein said antisense compound inhibits the expression of human RhoA.
Claim 3
Dependent Claim
11 words
The antisense compound of claim 1 which is an antisense oligonucleotide.
Claim 4
Dependent Claim
46 words
The antisense compound of claim 2 comprising SEQ ID NO: 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 22, 23, 24, 25, 27, 28, 29, 30, 31, 33, 34, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46 or 47.
Claim 5
Dependent Claim
26 words
The antisense compound of claim 2 comprising SEQ ID NO: 8, 11, 13, 24, 25, 27, 28, 29, 34, 38, 39, 41, 42, 45 or 46.
Claim 6
Dependent Claim
14 words
The antisense compound of claim 2 which comprises at least one modified internucleoside linkage.
Claim 7
Dependent Claim
15 words
The antisense compound of claim 5 wherein the modified internucleoside linkage is a phosphorothioate linkage.
Claim 8
Dependent Claim
14 words
The antisense compound of claim 2 which comprises at least one modified sugar moiety.
Claim 9
Dependent Claim
16 words
The antisense compound of claim 7 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
Claim 10
Dependent Claim
13 words
The antisense compound of claim 2 which comprises at least one modified nucleobase.
Claim 11
Dependent Claim
13 words
The antisense compound of claim 9 wherein the modified nucleobase is a 5-methylcytosine.
Claim 12
Dependent Claim
11 words
The antisense compound of claim 1 which is a chimeric oligonucleotide.
Claim 13
Dependent Claim
35 words
A method of inhibiting the expression of RhoA in human cells or tissues comprising contacting said cells or tissues in vitro with the antisense compound of claim 1 so that expression of RhoA is inhibited.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2002-08-30 | 2003-03-01 | 2003-08-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2006-08-30 | 2007-03-01 | 2007-08-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2010-08-30 | 2011-03-01 | 2011-08-31 | $7700.00 | Window Closed / Lapsed |